Benzinga | Oct 14, 2020 08:34AM EDT

Nasdaq Grants VistaGen 180-Day Extension To Meet Minimum Bid Price Requirement

SOUTH SAN FRANCISCO, Calif., Oct. 14, 2020 /PRNewswire/ -- VistaGen Therapeutics (NASDAQ:VTGN), a biopharmaceutical company developing new generation medicines for anxiety, depression and other central nervous system (CNS) disorders, today announced that the Company received written notification from the Listing Qualification Department of The NASDAQ Capital Market ("Nasdaq") granting the Company's request for a 180-day extension to regain compliance with Nasdaq's minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) (the "Rule"). The Company now has until April 12, 2021 to meet the requirement.